Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes.
Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes.
复制标题
吡格列酮可降低 2 型糖尿病患者的血浆血管紧张素 II 浓度。
DOI：
10.5551/jat.4002
复制
发表时间：
2010
影响因子：
4.4
通讯作者：
K. Shirai
中科院分区：
文献类型：
--
作者：
A. Saiki;M. Ohira;K. Endo;Nobukiyo Koide;T. Oyama;T. Murano;Y. Miyashita;K. Shirai
目的
脂肪细胞表达肾素-血管紧张素系统（RAS）的所有组分，并且脂肪细胞RAS调节脂肪细胞分化和代谢。血浆血管紧张素II（AII）是脂肪细胞RAS产生的假定标志物。本研究旨在探讨吡格列酮对2型糖尿病（T2 D）患者血浆AII的影响。
方法
将50例日本T2 D受试者随机分配至两组。一组给予吡格列酮30 mg/d（吡格列酮组），另一组不给予吡格列酮（对照组），持续16周。肝素前血清中的脂蛋白脂肪酶质量（LPL质量）作为脂肪细胞衍生因子和胰岛素敏感性的标志物进行测量。
结果
在吡格列酮组中，平均HbA 1c降低（p<0.0001），LPL质量增加（p<0.0001），血浆AII降低（p=0.0007），而对照组中这些参数无变化。吡格列酮组血浆AII的变化与LPL质量的变化呈负相关（r=-0.312）。在吡格列酮组中，基线血浆AII较高的亚组中血浆AII的降低幅度高于（p=0.0002），LPL质量的增加幅度倾向于高于（p=0.0941）血浆AII较低的亚组。
结论
本研究表明，吡格列酮降低血浆AII与T2 D中LPL质量增加相关。吡格列酮的胰岛素增敏作用可能与抑制脂肪细胞RAS有关。
AIM
Adipocytes express all components of the renin-angiotensin system (RAS), and adipocyte RAS regulates adipocyte differentiation and metabolism. Plasma angiotensin II (AII) is a putative marker of adipocyte RAS production. The aim of this study was to investigate the effect of pioglitazone on plasma AII in type 2 diabetes (T2D).
METHODS
Fifty Japanese subjects with T2D were randomly allocated to two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group) and the other group was not given pioglitazone (control group) for 16 weeks. Lipoprotein lipase mass in preheparin serum (LPL mass) was measured as an adipocyte-derived factor and a marker of insulin sensitivity.
RESULTS
In the pioglitazone group, the mean HbA1c decreased (p<0.0001), LPL mass increased (p<0.0001), and plasma AII decreased (p=0.0007), whereas these parameters were unchanged in the control group. The change in plasma AII correlated negatively with the change in LPL mass (r=-0.312) in the pioglitazone group. In the pioglitazone group, the decrease in plasma AII was higher (p=0.0002) and the increase in LPL mass tended to be higher (p=0.0941) in the subgroup with higher baseline plasma AII than that with lower plasma AII.
CONCLUSIONS
The present study indicates that pioglitazone decreases plasma AII associated with an increase in LPL mass in T2D. The insulin-sensitizing effect of pioglitazone may be involved in suppressing adipocyte RAS.